Tag: Arca biopharma

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update.

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA biopharma and Oruka Therapeutics announce Merger Agreement ARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted […]

ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19

rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy Topline trial data anticipated in the second quarter of 2021 Data […]

SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators

Integrin A5 may be a new target for intervening in the cell infectious process Findings may lead to the development of precision therapeutic approaches to prevent SARS-CoV-2-cell entry while preserving the functional activity of ACE2 WESTMINSTER and AURORA, Colo., July […]

ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

WESTMINSTER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted an amendment to its Special Protocol Assessment (SPA)request to […]